RxDoctor Payments Data

Parand Alavi, MD

Internal Medicine · Glenn Dale, MDNPI 1801976139

Payments from drug & device makers

$18,120in general payments, 2019–2025

Across 1,007 payments — averaging $17.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • AstraZeneca$2K
  • Lilly USA, LLC$1K
  • Amgen$1K
  • GSK$1K
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$18,087100%
  • Education$330%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk143$2,225
AbbVie(2 entities)115$2,122
AstraZeneca(2 entities)87$1,689
Lilly USA, LLC86$1,442
Amgen(2 entities)80$1,239
GSK56$1,096
Sanofi-aventis U.S. LLC59$1,069
Pfizer61$1,059
Novartis41$688
Bayer18$417
Exact Sciences15$374
Vanda Pharmaceuticals Inc.14$342
Amarin Pharma, Inc.17$332
Corcept Therapeutics12$313
Abbott14$302
Boehringer Ingelheim14$263
Astellas Pharma US Inc14$262
Kowa Pharmaceuticals America, Inc.14$229
Arbor Pharmaceuticals, Inc.15$211
Johnson & Johnson8$201
Lundbeck LLC10$179
Merck12$167
Shield Therapeutics Inc7$165
Endo Pharmaceuticals Inc.9$152
Ironwood Pharmaceuticals, Inc8$117
Currax Pharmaceuticals LLC7$112
Biohaven Pharmaceutical Holding Company Ltd.5$95
Phathom Pharmaceuticals, Inc.5$90
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC4$77
Biohaven Pharmaceuticals, Inc.5$74
E.r. Squibb & Sons, L.L.C.3$66
Axsome Therapeutics, Inc.3$63
Teva Pharmaceuticals USA, Inc.3$62
Jazz Pharmaceuticals Inc.3$59
Idorsia Pharmaceuticals US Inc2$46
Dexcom, Inc.1$41
Regeneron Healthcare Solutions, Inc.2$40
Gilead2$35
ANI Pharmaceuticals, Inc.2$34
Almatica Pharma LLC2$34
Inspire Medical Systems, Inc.1$33
Azurity Pharmaceuticals, Inc.2$33
Xeris Pharmaceuticals, Inc.2$32
Takeda Pharmaceuticals U.S.A., Inc.2$31
VBI Vaccine (delaware) Inc.2$29
Esperion Therapeutics, Inc.1$24
IBSA Pharma Inc.1$23
Hologic Sales And Service, LLC1$23
Daiichi Sankyo Inc.1$23
Antares Pharma, Inc.1$22
Genentech USA, Inc.1$21
Radius Health, Inc.1$20
Sumitomo Pharma America, Inc.1$19
Cumberland Pharmaceuticals, Inc.1$19
Bausch Health US, LLC1$19
Insulet Corporation1$19
Redhill Biopharma Inc.1$18
Hikma Pharmaceuticals USA1$18
Avanir Pharmaceuticals, Inc.1$18
Kaleo, Inc.1$17

How this compares

$18,120 in reported general payments places this provider in the 95th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$100,654
Medicare patients
313
Services billed
1,266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide55$78,165
OzempicSemaglutide40$47,553
EliquisApixaban43$41,258
RybelsusSemaglutide11$19,435
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$17,816
JanumetSitagliptin Phos/Metformin Hcl13$12,574
JardianceEmpagliflozin12$11,385
XareltoRivaroxaban11$7,225
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$5,721
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$2,799
Clonidine12$1,845
Diltiazem 24hr Er (Cd)Diltiazem Hcl12$1,493
PaxlovidNirmatrelvir/Ritonavir12$1,429
Rosuvastatin Calcium87$1,381
Atorvastatin Calcium128$1,313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$1,442$78,16555 claims
Novo NordiskOzempic, Rybelsus$2,225$66,98951 claims
PfizerEliquis, Paxlovid$1,059$42,68755 claims
MerckJanumet$167$12,57413 claims
Boehringer IngelheimJardiance$263$11,38512 claims
Johnson & JohnsonXarelto$201$7,22511 claims
ANI Pharmaceuticals, Inc.Valsartan$34$31320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Glenn Dale

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →